Analgesics, also known as painkillers, are used to treat and reduce pain in the body. Typically, they are used when the pain is severe and becomes unbearable for the patient. Non-opioids, opioids, and compound analgesics (a combination of both opioids and non-opioids) are the major analgesic products used globally. The emergence of analgesics is mainly attributed to the increase in acute and chronic diseases, as well as the rising incidence of cancer worldwide.

Opioid drugs are the strongest types of analgesics, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only.

The world analgesics market is expected to achieve moderate growth in the near future, majorly because of factors such as increase in cardiovascular disease, cancer, and arthritis and growing geriatric population. Recurring pain and aches experienced by the ageing population is another factor the helps the market growth. In addition, increasing investments in R&D by the public and private sector, with key emphasis on the classes of compounds for formulating new therapeutics, are further expected to drive the market. However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are likely to restrain the growth of the market.

The report segments the analgesics market on the basis of type, route of administration, and geography. On the basis of type, the market is segmented into non-opioids and opioids. According to the route of administration, it is segmented into oral, intravenous, rectal, transdermal, and topical. Based on the geography, it is categorized into North America, Europe, Asia-Pacific, andLAMEA.

Companies adopt acquisition as their key development strategy in the analgesic market. A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.

KEY BENEFITS FOR STAKEHOLDERS:

This report includes a detailed quantitative analysis of the current market trends and estimations from 2015 to 2022, which assists in identifying the prevailing market opportunities.
Geographically, the analgesics market is analyzed based on key regions such as North America, Europe, Asia-Pacific, andLAMEA.
This study evaluates the competitive landscape of the analgesics market to aid the reader in understanding the competitive environment across the geographic locations.
Furthermore, key market players within this market have been profiled in this report and their strategies are analyzed thoroughly. This helps in understanding the competitive outlook on the supply side of the market.
Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
Porters Five Forces analysis extensively covers the perspective of buyers and suppliers, along with the competitive rivalry among companies.
SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.

ANALGESICS MARKET KEY SEGMENTS:

By Type
Non-opioids
Opioids
By Route of Administration
Oral
Intravenous
Rectal
Transdermal
Topical
By Geography
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
Spain
Sweden
France
Russia
Denmark
Rest of EU
Asia-Pacific
Japan
China
India
Australia
Indonesia
Rest of APAC
LAMEA
Brazil
Venezuela
Chile
Saudi Arabia
UAE
Morocco
Kenya
Nigeria
Rest ofLAMEA